About Reata Pharmaceuticals (NASDAQ:RETA)
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia, mitochondrial myopathies and metastatic melanoma.
Industry, Sector and Symbol:
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Sector: Healthcare
- Symbol: NASDAQ:RETA
- CUSIP: N/A
- Web: reatapharma.com
- Debt-to-Equity Ratio: -0.15%
- Current Ratio: 3.18%
- Quick Ratio: 3.18%
Sales & Book Value:
- Annual Sales: $49.86 million
- Price / Sales: 13.05
- Book Value: ($5.07) per share
- Price / Book: -4.92
- Trailing EPS: ($1.46)
- Net Income: $-6,220,000.00
- Net Margins: -69.44%
- Return on Assets: -34.36%
- Employees: 75
- Outstanding Shares: 26,110,000
Frequently Asked Questions for Reata Pharmaceuticals (NASDAQ:RETA)
What is Reata Pharmaceuticals' stock symbol?
Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."
How were Reata Pharmaceuticals' earnings last quarter?
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) released its quarterly earnings results on Monday, November, 13th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.39) by $0.11. The company had revenue of $12.60 million for the quarter, compared to analysts' expectations of $12.54 million. The firm's quarterly revenue was up .0% on a year-over-year basis. View Reata Pharmaceuticals' Earnings History.
Where is Reata Pharmaceuticals' stock going? Where will Reata Pharmaceuticals' stock price be in 2017?
8 Wall Street analysts have issued 12 month target prices for Reata Pharmaceuticals' shares. Their predictions range from $43.00 to $78.00. On average, they expect Reata Pharmaceuticals' stock price to reach $54.71 in the next year. View Analyst Ratings for Reata Pharmaceuticals.
What are Wall Street analysts saying about Reata Pharmaceuticals stock?
Here are some recent quotes from research analysts about Reata Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States. " (11/16/2017)
- 2. Cowen and Company analysts commented, "RETA reported 3Q17 financials yesterday, noting that the three major programs." (11/14/2017)
- 3. Piper Jaffray Companies analysts commented, "We hosted Reata for investor meetings and came away with positive insights on its clinical progress in CTD-PAH, Friedreich's Ataxia, and other orphan disorders. On CTDPAH, we believe the CATALYST trial is progressing well and were reminded as to why we're confident in this capital-efficient trial design. In FA, we look forward to 'hypothesisgenerating' results in mid'17 which could demonstrate the first activity from omav' in a neurodegenerative condition ' potentially opening the door to a pivotal program in FA and/ or studies in other indications. To set up these results, we're hosting a KOL call on FA next Monday 4/3/17 ' contact your PJC rep for details. Overall, we expect Reata could conduct pivotal stage programs in 3+ orphan indications within the next 12 months, and continue to see this platform as under-valued compared to other multi-candidate, platform-enabled drug developers. In advance of clinical progress yet in 2017, we reiterate OW." (3/28/2017)
- 4. Stifel Nicolaus analysts commented, "Our positive thesis centers on what we see as blockbuster potential for lead asset bardoxolone methyl (BARD) in chronic kidney disease (CKD) caused by Alport syndrome. Yes, it's true that investors previously abandoned BARD in CKD after the P3 BEACON trial was halted in 2012 due to serious adverse events ' but we and our KOL consultants believe the underlying causes behind the prior safety issues are now well characterized and understood - and importantly, are prospectively controlled for in ongoing clinical trials - and therefore unlikely to re-emerge. Strong BARD efficacy across multiple prior CKD trials makes us confident that the drug will work as expected when initial P2 data are announced in 2H17. We are also sanguine on the BARD opportunity in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), with P3 data expected in 1H18. Over the next 12-18 months we see four distinct clinical catalysts that hold potential for significant value creation ' and we recommend investors go long ahead of them." (2/22/2017)
- 5. Robert W. Baird analysts commented, "Though Reata's lead asset, bardoxolone methyl, has been plagued by safety concerns in the past, we think the company has gotten its groove back. With multiple readouts over the next two years in high unmet need indications and a valuation implying more failures than successes, we think the stock is significantly undervalued and see potential for upward momentum over the next 12-18 months. Initiating at Outperform with a $43 price target." (1/24/2017)
Who are some of Reata Pharmaceuticals' key competitors?
Some companies that are related to Reata Pharmaceuticals include Sangamo Therapeutics (SGMO), Radius Health (RDUS), Dynavax Technologies Corporation (DVAX), Ignyta (RXDX), Athenex (ATNX), Lexicon Pharmaceuticals (LXRX), Neuroderm Ltd (NDRM), Dermira (DERM), Xencor (XNCR), REGENXBIO (RGNX), Acorda Therapeutics (ACOR), Amarin Corporation PLC (AMRN), Omeros Corporation (OMER), Epizyme (EPZM), Intra-Cellular Therapies (ITCI), Flexion Therapeutics (FLXN), Retrophin (RTRX) and Audentes Therapeutics (BOLD).
Who are Reata Pharmaceuticals' key executives?
Reata Pharmaceuticals' management team includes the folowing people:
- J. Warren Huff, Chairman of the Board, President, Chief Executive Officer (Age 63)
- Jason Dauglas Wilson CPA, Chief Financial Officer and Vice President, Strategy (Age 47)
- Colin John Meyer MD, PhD, Chief Medical Officer and Vice President, Product Development (Age 38)
- Keith Wayne Ward, Vice President, Chief Development Officer (Age 47)
- Michael D. Wortley, Vice President, Chief Legal Officer (Age 69)
- Dawn C. Bir, Chief Commercial Officer (Age 46)
- William D. McClellan Jr. CPA, Director (Age 57)
- James Edward Bass, Independent Director (Age 58)
- R. Kent McGaughy Jr., Independent Director (Age 45)
- Jack B. Nielsen, Independent Director (Age 53)
When did Reata Pharmaceuticals IPO?
(RETA) raised $60 million in an initial public offering (IPO) on Thursday, May 26th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.
Who owns Reata Pharmaceuticals stock?
Reata Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Emerald Advisers Inc. PA (3.06%), Emerald Mutual Fund Advisers Trust (2.54%), JPMorgan Chase & Co. (0.88%), Sphera Funds Management LTD. (0.79%), Alyeska Investment Group L.P. (0.35%) and Crestline Management LP (0.23%). Company insiders that own Reata Pharmaceuticals stock include A/S Novo, Abbvie Inc, Colin John Meyer, Cpmg Inc, Jack Nielsen, James Edward Bass, James W Traweek Jr, James Warren Huff and R Kent Mcgaughy Jr. View Institutional Ownership Trends for Reata Pharmaceuticals.
Who sold Reata Pharmaceuticals stock? Who is selling Reata Pharmaceuticals stock?
Reata Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co.. Company insiders that have sold Reata Pharmaceuticals company stock in the last year include A/S Novo and Abbvie Inc. View Insider Buying and Selling for Reata Pharmaceuticals.
Who bought Reata Pharmaceuticals stock? Who is buying Reata Pharmaceuticals stock?
Reata Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Emerald Mutual Fund Advisers Trust, Emerald Advisers Inc. PA, Alyeska Investment Group L.P., Crestline Management LP, Candriam Luxembourg S.C.A., Ameriprise Financial Inc. and P.A.W. Capital Corp. Company insiders that have bought Reata Pharmaceuticals stock in the last two years include A/S Novo, Colin John Meyer, Cpmg Inc, Jack Nielsen, James Edward Bass, James W Traweek Jr, James Warren Huff and R Kent Mcgaughy Jr. View Insider Buying and Selling for Reata Pharmaceuticals.
How do I buy Reata Pharmaceuticals stock?
Shares of Reata Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Reata Pharmaceuticals' stock price today?
One share of Reata Pharmaceuticals stock can currently be purchased for approximately $24.92.
How big of a company is Reata Pharmaceuticals?
Reata Pharmaceuticals has a market capitalization of $653.91 million and generates $49.86 million in revenue each year. The company earns $-6,220,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis. Reata Pharmaceuticals employs 75 workers across the globe.
How can I contact Reata Pharmaceuticals?
Reata Pharmaceuticals' mailing address is 2801 Gateway Dr Ste 150, IRVING, TX 75063, United States. The company can be reached via phone at +1-972-8652206 or via email at [email protected]
MarketBeat Community Rating for Reata Pharmaceuticals (RETA)MarketBeat's community ratings are surveys of what our community members think about Reata Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Reata Pharmaceuticals (NASDAQ:RETA) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 8 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$54.71 (119.56% upside)|
Consensus Price Target History for Reata Pharmaceuticals (NASDAQ:RETA)
Analysts' Ratings History for Reata Pharmaceuticals (NASDAQ:RETA)
(Data available from 11/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/14/2017||Cowen and Company||Reiterated Rating||Buy||N/A|
|10/24/2017||Robert W. Baird||Reiterated Rating||Buy||$47.00||N/A|
|10/6/2017||Jefferies Group LLC||Reiterated Rating||Buy||$44.00||N/A|
|9/13/2017||Leerink Swann||Initiated Coverage||Outperform -> Outperform||$43.00||Medium|
|8/23/2017||Citigroup Inc.||Reiterated Rating||Buy||$87.00 -> $78.00||High|
|7/26/2017||Ladenburg Thalmann Financial Services||Reiterated Rating||Buy||$55.00 -> $61.00||High|
|7/25/2017||Stifel Nicolaus||Reiterated Rating||Buy||$38.00 -> $50.00||High|
|7/24/2017||Piper Jaffray Companies||Boost Price Target||Buy||$53.00 -> $60.00||High|
Earnings History and Estimates Chart for Reata Pharmaceuticals (NASDAQ:RETA)
Earnings History by Quarter for Reata Pharmaceuticals (NASDAQ RETA)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/13/2017||Q3 2017||($0.39)||($0.50)||$12.54 million||$12.60 million||View||N/A|
|11/14/2016||Q316||($0.14)||($0.04)||$12.46 million||$12.55 million||View||N/A|
Earnings Estimates for Reata Pharmaceuticals (NASDAQ:RETA)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Reata Pharmaceuticals (NASDAQ:RETA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Reata Pharmaceuticals (NASDAQ RETA)
Insider Ownership Percentage: 62.40%
Institutional Ownership Percentage: 21.88%
Insider Trades by Quarter for Reata Pharmaceuticals (NASDAQ RETA)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/15/2017||James Edward Bass||Director||Buy||3,888||$24.02||$93,389.76|| |
|8/1/2017||James Edward Bass||Director||Buy||8,064||$31.00||$249,984.00|| |
|6/14/2017||A/S Novo||Major Shareholder||Sell||61,000||$25.11||$1,531,710.00|| |
|6/13/2017||A/S Novo||Major Shareholder||Sell||11,389||$25.47||$290,077.83|| |
|6/12/2017||A/S Novo||Major Shareholder||Sell||222,503||$25.71||$5,720,552.13|| |
|6/7/2017||A/S Novo||Major Shareholder||Sell||89,497||$28.24||$2,527,395.28|| |
|6/6/2017||A/S Novo||Major Shareholder||Sell||64,170||$28.09||$1,802,535.30|| |
|6/5/2017||A/S Novo||Major Shareholder||Sell||23,327||$28.67||$668,785.09|| |
|3/28/2017||Abbvie Inc.||Major Shareholder||Sell||450,000||$22.50||$10,125,000.00|| |
|12/30/2016||Cpmg Inc||Director||Buy||9,392||$21.72||$203,994.24|| |
|12/16/2016||Cpmg Inc||Director||Buy||164,753||$22.99||$3,787,671.47|| |
|12/15/2016||James W Traweek Jr||Major Shareholder||Buy||8,889||$21.57||$191,735.73|| |
|12/14/2016||James Edward Bass||Director||Buy||5,000||$21.76||$108,800.00|| |
|8/22/2016||Jack Nielsen||Director||Buy||1,780||$17.00||$30,260.00|| |
|8/18/2016||R Kent Mcgaughy Jr||Director||Buy||308,220||$17.08||$5,264,397.60|| |
|8/16/2016||Colin John Meyer||Insider||Buy||7,000||$16.26||$113,820.00|| |
|6/30/2016||James W Traweek Jr||Major Shareholder||Buy||164,600||$19.78||$3,255,788.00|| |
|6/27/2016||Cpmg Inc||Director||Buy||73,403||$19.26||$1,413,741.78|| |
|6/7/2016||R Kent Mcgaughy Jr||Director||Buy||24,220||$17.57||$425,545.40|| |
|6/1/2016||A/S Novo||Major Shareholder||Buy||750,000||$11.00||$8,250,000.00|| |
|6/1/2016||James Warren Huff||Insider||Buy||114,000||$11.00||$1,254,000.00|| |
|6/1/2016||R Kent Mcgaughy Jr||Director||Buy||251,553||$12.70||$3,194,723.10|| |
Latest Headlines for Reata Pharmaceuticals (NASDAQ RETA)
|Reata Pharmaceuticals, Inc. (RETA) Rating Lowered to Sell at Zacks Investment Research|
www.americanbankingnews.com - November 18 at 8:18 PM
|FY2017 EPS Estimates for Reata Pharmaceuticals, Inc. Cut by Leerink Swann (RETA)|
www.americanbankingnews.com - November 17 at 8:10 PM
|Jefferies Group Analysts Lower Earnings Estimates for Reata Pharmaceuticals, Inc. (RETA)|
www.americanbankingnews.com - November 17 at 8:08 PM
|Insider Buying: Reata Pharmaceuticals, Inc. (RETA) Director Acquires 3,888 Shares of Stock|
www.americanbankingnews.com - November 16 at 9:02 PM
|Cowen and Company Reiterates Buy Rating for Reata Pharmaceuticals, Inc. (RETA)|
www.americanbankingnews.com - November 14 at 11:02 PM
|Reata Pharmaceuticals, Inc. (RETA) Issues Earnings Results, Misses Expectations By $0.11 EPS|
www.americanbankingnews.com - November 14 at 11:24 AM
|Reata Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial and Operating Results|
finance.yahoo.com - November 14 at 7:17 AM
|Is a Surprise Coming for Reata Pharmaceuticals (RETA) This Earnings Season?|
finance.yahoo.com - November 9 at 12:31 PM
|Reata Pharmaceuticals, Inc. (RETA) Given Consensus Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - November 9 at 3:38 AM
|Reata Provides Update on Bardoxolone Methyl from the American Society of Nephrology Kidney Week Meeting|
finance.yahoo.com - November 7 at 9:34 AM
|Reata Announces Primary Results from the Phase 2 CARDINAL Study of Bardoxolone in Alport Syndrome at the American Society of Nephrology Kidney Week 2017 Annual Meeting|
finance.yahoo.com - November 4 at 10:52 AM
|$12.59 Million in Sales Expected for Reata Pharmaceuticals, Inc. (RETA) This Quarter|
www.americanbankingnews.com - November 3 at 8:52 AM
|Reata Pharmaceuticals, Inc. – Value Analysis (NASDAQ:RETA) : October 30, 2017|
finance.yahoo.com - October 31 at 8:39 AM
|ETFs with exposure to Reata Pharmaceuticals, Inc. : October 26, 2017|
finance.yahoo.com - October 27 at 1:59 PM
|Reata Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RETA-US : October 27, 2017|
finance.yahoo.com - October 27 at 1:59 PM
|Reata Pharmaceuticals (RETA) & Its Competitors Financial Analysis|
www.americanbankingnews.com - October 27 at 3:06 AM
|Reata Pharma (RETA) Says First Patient Enrolled in Part 2 of MOXIe Study of Omaveloxolone for the Treatment of FA|
www.streetinsider.com - October 25 at 9:48 AM
|Reata Pharmaceuticals, Inc. (RETA) Rating Reiterated by Robert W. Baird|
www.americanbankingnews.com - October 24 at 4:50 PM
|Reata Announces First Patient Enrolled in Part 2 of MOXIe Study of Omaveloxolone for the Treatment of Friedreich’s Ataxia|
finance.yahoo.com - October 24 at 9:14 AM
|Analyzing Reata Pharmaceuticals (RETA) and Aeglea BioTherapeutics (AGLE)|
www.americanbankingnews.com - October 22 at 6:26 PM
|Reata Announces Late-Breaking Presentation of Primary Results From Phase 2 CARDINAL Study at the American Society of Nephrology Kidney Week 2017 Annual Meeting|
finance.yahoo.com - October 20 at 3:56 PM
|Reata Pharmaceuticals (RETA) and Kythera Biopharmaceuticals (KYTH) Head to Head Analysis|
www.americanbankingnews.com - October 16 at 6:28 PM
| Analysts Expect Reata Pharmaceuticals, Inc. (RETA) Will Announce Quarterly Sales of $12.59 Million|
www.americanbankingnews.com - October 15 at 1:32 PM
|Reata Pharmaceuticals, Inc. (RETA) Receives Consensus Rating of "Buy" from Analysts|
www.americanbankingnews.com - October 15 at 4:46 AM
|Reviewing Reata Pharmaceuticals (RETA) & Its Rivals|
www.americanbankingnews.com - October 14 at 8:14 AM
|Zacks: Analysts Expect Reata Pharmaceuticals, Inc. (RETA) Will Announce Earnings of -$0.42 Per Share|
www.americanbankingnews.com - October 13 at 6:20 AM
|Jefferies Group LLC Reiterates Buy Rating for Reata Pharmaceuticals, Inc. (RETA)|
www.americanbankingnews.com - October 6 at 9:36 AM
| Brokerages Expect Reata Pharmaceuticals, Inc. (RETA) Will Announce Quarterly Sales of $12.59 Million|
www.americanbankingnews.com - September 26 at 3:28 AM
|-$0.42 EPS Expected for Reata Pharmaceuticals, Inc. (RETA) This Quarter|
www.americanbankingnews.com - September 24 at 2:28 PM
|4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid|
finance.yahoo.com - September 22 at 4:15 PM
|Reata Pharmaceuticals, Inc. (RETA) Given Average Rating of "Buy" by Brokerages|
www.americanbankingnews.com - September 20 at 4:44 AM
|New Strong Sell Stocks for September 15th|
www.zacks.com - September 15 at 8:10 AM
|Reata Pharmaceuticals, Inc. (RETA) Expected to Earn Q3 2017 Earnings of ($0.41) Per Share|
www.americanbankingnews.com - September 15 at 7:20 AM
|Reata Pharma (RETA) Announces FDA Orphan Drug Designation for Omaveloxolone for Treatment of Malignant Melanoma|
www.streetinsider.com - September 13 at 8:40 PM
|Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Omaveloxolone for the Treatment of Malignant Melanoma|
finance.yahoo.com - September 13 at 8:40 PM
|Leerink Swann Reiterates Outperform Rating for Reata Pharmaceuticals, Inc. (RETA)|
www.americanbankingnews.com - September 13 at 9:52 AM
|Reata Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : RETA-US : September 1, 2017|
finance.yahoo.com - September 2 at 8:02 AM
|Robert W. Baird Reaffirms Buy Rating for Reata Pharmaceuticals, Inc. (RETA)|
www.americanbankingnews.com - September 1 at 8:56 PM
|ETFs with exposure to Reata Pharmaceuticals, Inc. : September 1, 2017|
finance.yahoo.com - September 1 at 7:56 AM
|Equities Analysts Set Expectations for Reata Pharmaceuticals, Inc.'s Q3 2017 Earnings (RETA)|
www.americanbankingnews.com - September 1 at 6:56 AM
|Featured Company News - Sorrento Submits NDA for ZTlido Next-Gen Lidocaine Patch; Intends to File an MAA in Europe|
finance.yahoo.com - August 31 at 9:21 AM
|Featured Company News - Sorrento Submits NDA for ZTlido Next-Gen Lidocaine Patch; Intends to File an MAA in Europe|
finance.yahoo.com - August 31 at 9:21 AM
|Reata Pharmaceuticals, Inc. (RETA) Receives New Coverage from Analysts at Jefferies Group LLC|
www.americanbankingnews.com - August 30 at 10:28 AM
|Reata Pharmaceuticals, Inc. :RETA-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017|
finance.yahoo.com - August 26 at 8:47 AM
|Reata Pharmaceuticals, Inc. (RETA) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - August 26 at 4:34 AM
|Reata Pharmaceuticals, Inc. (RETA) Receives Buy Rating from Citigroup Inc.|
www.americanbankingnews.com - August 23 at 2:56 PM
|$12.63 Million in Sales Expected for Reata Pharmaceuticals, Inc. (RETA) This Quarter|
www.americanbankingnews.com - August 20 at 11:16 AM
|-$0.34 EPS Expected for Reata Pharmaceuticals, Inc. (RETA) This Quarter|
www.americanbankingnews.com - August 18 at 8:12 AM
|Reata Pharmaceuticals, Inc. – Value Analysis (NASDAQ:RETA) : August 15, 2017|
finance.yahoo.com - August 16 at 7:16 AM
|FDA Confirms That Use of mFARS as Primary Endpoint in Part 2 of the MOXIe Trial Can Support Approval of Omaveloxolone in Friedreich’s Ataxia|
finance.yahoo.com - August 15 at 6:40 AM
Reata Pharmaceuticals (NASDAQ RETA) Chart for Wednesday, November, 22, 2017